CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myeloma.
Benjamin T. Diamond, Linda Banovic Baughn, Mansour Poorebrahim, Alexandra Maria Poos, Holly Lee, Marcella Kaddoura, Julia Erin Wiedmeier, Michael A. Durante, Gregory E. Otteson, Dragan Jevremović, Hongwei Tang, Stefan Fröhling, Marc‐Andrea Baertsch, Marios Papadimitriou, Bachisio Ziccheddu, , Francesco Maura
This study identifies biallelic CD38 loss as a mechanism of resistance to anti-CD38 antibodies in multiple myeloma, with specific mutations affecting antibody efficacy.
Blood · Jun 10, 2025Peer-reviewedCancer Biology